Optimist would rather have 24 shots in the eye per year. LOL......And then he will call me an idiot!! LOL again!....Me: "Optimist want to go golfing today?" Opti: "No, I can't..... I have to get another shot in my eye" Me: "didn't you just get a shot in the eye 2 weeks ago?" Opti: "you are an idiot...."
Phase 3 will be starting 1H 2015. Visual improvement data looks strong. So, it well take some market share from Fovista, maybe completely.
Thank you Joey. Great answer! That is the type of financial answer I was looking for. Even with the poke at the end (I probably deserved it)
Well....I was asking for an intelligent answer to my question. There have been several responses....and I am still looking for an intelligent response. I'm not looking for a medical answer (I am comfortable with my medical evaluation of the situation). I am a physician. I am looking for someone with a financial background to give an intelligent answer....If the PSCK9 inhibitor does well as I anticipate, and Alfrezza does not, what are the stock implications.......Even if you disagree with this, what do you think would happen.
FYI inhaled insulin was on the market a few years ago, it was pulled from the market by Pfizer because of poor sales. My total scripts for that product was ZERO.
So I would appreciate any intelligent response (Clevans, Creditescueny and oxotnik do not fit this criteria)
I have been considering an investment in SNY. I am especially optimistic on the PCSK9 cholesterol meds (I am a physician and treat lots of hyperlipidemia and lots of diabetes). I am personally less optimistic about inhaled insulin. I struggle with the unknown lung toxicity over longer periods of time and the injectable pens are easy for patients to use. So my question is, how will the stock do if the PCSK9 med is a hit and afrezza is a bit disappointing. I appreciate others thoughts on the investment potential IF (yes, it is an if, but I was ready to by SNY just before the MNKD deal, I stepped back) my scenario is correct.
Only one patient out of the 20 required an injection of
Lucentis at week 10 using predefined OCT based rescue criteria. I bet we end up with similar or superior vision and LESS SHOTS than standard therapy.
yeah, but these are drops.....Only one patient out of the 20 required an injection of
Lucentis at week 10 using predefined OCT based rescue criteria
According to a tweet from Retina Today (and re-tweet from OHRP)....Eyes with RVO treated with squalamine drops had a 20.3-letter gain at 10 weeks, according to John Wroblewski, MD
So, if confirmed true, looks like were are 2 for 2 on vision improvment. Nice! Wonder if Adam F thinks it is still not getting to the back of the eye?? This week should be interesting. Jason speaks on Tuesday at ASRS.
I agree. Sheep is a short seller and does not scare anyone. This market pullback will be a buying opportunity for CGEN and for the market.
Greetings. I am a primary care physician. I attended a conference recently and it looks like the PCSK9 inhibitors will get market share especially for the 10% of patients that are statin intolerant. They seem to be very well tolerated and lower LDL by about 70%. . I'm looking to purchase some shares of either REGN or SNY. I'm looking for advise REGN vs SNY (I realize I'm on the REGN board so the bias likely will be to REGN). I already own several biotech stocks and SNY has a decent dividend. Can others give me some reasons REGN vs SNY? (or should I own a bit of both if I like this class of meds). I appreciate the thoughts....
I bought at 1, 2, 3, 4, 5 and 6.(not in that order ) I'm happy in the 8s. I can't wait to see where this stock is in 2 years. Double O five will be the dollars left in your trading account if you keep your short position on.....Watch and learn..
Indexes were already in. You have another SA article after hours today. Maybe you can try another SA article tomorrow as well. Maybe next week, another SA article. Then maybe AF again. Mid July, another SA article. Listen to the conference call, vision improved!!!
AF at the street, multiple SA articles and multiple short sellers on this board all throwing bombs with questionable information. This is an unsuccessful bear raid and here comes a short squeeze!!
Hi Stewart. How many years away is gene therapy? A lot of drops should be used before then. Also, most places in the world will need a more simple solution. (think globally while investing)
You are correct! Many investing mistakes are made because people do not think globally enough. The eye drops will be a monster product.......globally. Smart institutions are seeing this. Shorts see the truck that is about to run them over.